After a catastrophic second wave of COVID-19 in India since April
which has seen its overall death toll climb to almost 400,000,
thousands who contracted the virus also suffered from a rare fungal
disease called mucormycosis, or "black fungus". [
The South Asian country -- which has more than 30.4 million
confirmed COVID-19 infections, second only to the United States --
has so far reported more than 40,845 cases of mucormycosis.
Many like Shinde may never be able to regain their sight after the
fungal disease which causes blackening or discoloration over the
nose, blurred or double vision, chest pain, breathing difficulties
and coughing blood.
"Father was fit and healthy, now he doesn't feel like eating ..."
said his daughter, who did not want to be named. "His teeth have
also been removed, it's very sad."
Shinde, from the arid western Indian region of Marathwada, will
resume work after he recovers from this, his daughter told Reuters
in Mumbai.
Reuters spoke to several other sufferers of mucormycosis across
India.
[to top of second column] |
Adesh Kumar, a 39-year-old
farmer in the northern state of Uttar Pradesh,
lost sight in his left eye. He had to borrow
money to pay for medicine, secured against some
of his land. India ordered
tighter surveillance of mucormycosis in May as it compounded the
challenge for COVID-19 patients, especially those on steroid therapy
and with diabetes. Experts say an overuse of certain drugs which
suppress the immune system could be causing the surge of the fungal
infection.
"We are seeing a lot of mucormycosis cases post COVID infections,
since COVID itself is known to decrease the immunity," said Charuta
Mandke of the ophthalmology department at Dr R N Cooper Municipal
General Hospital in Mumbai.
(Reporting by Amit Dave in Ahmedabad, Adnan Abidi in New Delhi and
Francis Mascarenhas in Mumbai, Writing by Ankur Banerjee in
Bengaluru; Editing by Emelia Sithole-Matarise)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content
|